01
Quality assessment and control design
Review protocols, data flows, systems, quality plans, edit checks, reconciliation processes, issue logs and governance to identify material gaps and prioritise controls.
Healthcare and Life Sciences Service
Clinical Trial Data Quality Services for Reliable Study Decisions
DataConsultant helps sponsors, CROs and clinical technology teams design, assess and operate risk-based controls for trial data. The service covers critical-data definition, validation, reconciliation, issue management, oversight and documentation so study teams can identify material problems earlier and support dependable analysis, database lock and inspection readiness.
- Critical-to-quality data focus
- Cross-source reconciliation controls
- Documented issue and escalation model
- Vendor-neutral quality oversight
Study Data Quality Control ViewIllustrative example
Risk-basedreview coverage
Critical endpoint dataPriority review
Safety reconciliationOpen items tracked
External data transfersAcceptance checks
Query ageingEscalation rules
Capture
Validate
Reconcile
Resolve
What is a Clinical Trial Data Quality Service?
A clinical trial data quality service is a structured approach to assessing and improving whether study data are complete, consistent, traceable, timely and fit for their intended scientific and regulatory use. It commonly supports sponsors, CROs and study teams through critical-data identification, quality planning, validation-rule design, cross-system reconciliation, central review, issue governance and quality reporting. Typical buyers include clinical data management, clinical operations, quality, biostatistics and regulatory leaders. The service depends on protocol clarity, system access, vendor cooperation and accountable clinical judgement; it supports but does not replace sponsor oversight, legal advice or regulatory decisions.
Service offering
What DataConsultant Can Provide
The scope can be configured for one study, a portfolio, a remediation programme or an ongoing quality operation.
02
Implementation and remediation
Define rule catalogues, quality indicators, dashboards, reconciliation matrices, operating procedures and remediation backlogs, then support controlled implementation and validation.
03
Operational quality support
Provide recurring data review, issue triage, trend analysis, vendor oversight, reporting, escalation and knowledge transfer through an agreed managed-service model.
Better focus
Concentrate review effort on data and processes that materially affect participant safety, endpoints and decisions.
Clearer ownership
Define who detects, assesses, resolves, approves and reports each class of quality issue.
Earlier visibility
Use indicators and trends to identify emerging problems before database lock pressure increases.
Stronger evidence
Maintain traceable decisions, control records, issue histories and quality reporting for oversight.
Problems and response
Clinical Data Quality Problems the Service Addresses
Inconsistent critical data
Endpoint, eligibility, exposure or safety data differ across sources or remain incomplete.
Late issue discovery
Quality signals are found close to interim analysis or database lock, leaving limited remediation time.
Fragmented vendor oversight
Responsibilities, acceptance checks and escalation routes vary across CROs and specialist providers.
High query burden
Large rule inventories generate low-value queries while material risks receive insufficient attention.
How the response is structured
- Prioritise
- Identify critical-to-quality factors and connect them to data, processes and controls.
- Standardise
- Define rules, issue categories, ownership, evidence and acceptance criteria.
- Monitor
- Track meaningful indicators, trends, exceptions, ageing and recurring root causes.
- Resolve
- Coordinate investigation, correction, preventive action, approval and closure evidence.
Clarify the highest-risk data quality gaps
Start with a focused assessment of protocols, systems, vendors, controls and current issue patterns.
Suitability
Who the Service Is For
Good fit
- Sponsors managing complex or multi-source trials
- Teams preparing for interim analysis or database lock
- Organisations strengthening CRO and vendor oversight
- Portfolios with recurring data-quality or reconciliation issues
- Clinical technology programmes changing EDC or data platforms
May not be the right fit
- A narrow platform defect requiring only vendor support
- A request for legal advice or guaranteed regulatory acceptance
- A statistical analysis task without a data-quality workstream
- A programme without access to accountable study stakeholders
- A need for statutory audit or formal certification only
Applications
Common Clinical Trial Data Quality Use Cases
Database lock readiness
Assess outstanding critical data, query ageing, reconciliations, coding, deviations and unresolved vendor dependencies.
External data reconciliation
Define transfer acceptance, matching logic, discrepancy management and sign-off for laboratories, imaging, eCOA or device data.
Risk-based quality monitoring
Connect critical-to-quality factors to indicators, thresholds, trend review, escalation and documented follow-up.
Edit-check optimisation
Review rule value, redundancy, false positives, manual review burden and alignment with protocol risk.
Vendor transition or rescue
Establish a controlled baseline, open-item inventory, ownership model and handover evidence during provider change.
Portfolio quality standardisation
Create common taxonomies, reporting definitions, oversight forums and reusable controls across studies.
Capabilities
Clinical Trial Data Quality Capabilities
Assessment and planning
Establish the evidence base and risk priorities.
- Protocol and data-flow review
- Critical data and process mapping
- Current-state maturity assessment
- Control and documentation gap analysis
- Quality risk register
- Prioritised remediation plan
Validation and reconciliation
Design controls across internal and external sources.
- Edit-check and manual-review design
- Transfer acceptance controls
- Cross-system reconciliation
- Medical coding review support
- Duplicate and consistency checks
- Traceability and audit evidence
Oversight and operations
Operate a repeatable issue and reporting model.
- Quality indicators and dashboards
- Issue taxonomy and triage
- Root-cause and recurrence analysis
- Vendor service review
- Escalation and decision logs
- Knowledge transfer and training
Deliverables
Expected Deliverables
Final outputs are agreed during discovery and tailored to study phase, operating model and existing documentation.
| Deliverable | Purpose | Typical contents | Primary users |
|---|---|---|---|
| Data quality assessment | Establish current risks and control gaps | Findings, evidence, severity, dependencies and recommendations | Quality, data management, clinical operations |
| Critical data and process map | Focus controls on material trial factors | Endpoints, safety, eligibility, exposure, deviations and source links | Study team, medical, statistics |
| Rule and review catalogue | Document automated and manual checks | Logic, rationale, priority, owner, frequency and acceptance criteria | Data management, programmers, vendors |
| Reconciliation matrix | Control cross-source consistency | Sources, keys, timing, discrepancy rules, owners and sign-off | Clinical operations, safety, vendors |
| Quality oversight dashboard | Support recurring governance | Indicators, thresholds, trends, ageing, actions and escalation status | Sponsor oversight and programme governance |
| Remediation and operating pack | Mobilise correction and sustainable operation | Backlog, SOP updates, RACI, decision log, training and handover | Programme, quality and operational teams |
Define a practical deliverable set
Align outputs to study decisions, sponsor oversight, inspection readiness and operational adoption.
Delivery process
How DataConsultant Delivers the Service
Discovery and alignment
Confirm study context, decisions, quality concerns, stakeholders and scope boundaries.
Output: agreed scope and evidence requestCurrent-state assessment
Review protocols, plans, systems, data flows, rules, reconciliations, vendors and issue history.
Output: evidence-based findingsRisk prioritisation
Identify critical data and processes, material failure modes, dependencies and control priorities.
Output: quality risk and control mapSolution design
Define target rules, indicators, ownership, workflows, dashboards and documentation requirements.
Output: approved quality designImplementation and validation
Configure or document controls, test their operation, manage issues and support remediation.
Output: validated control set and backlogTransition and improvement
Transfer knowledge, establish reporting, monitor performance and refine controls using evidence.
Output: operating model and improvement cycleTechnology and standards
Platforms, Data Sources and Reference Frameworks
Delivery is platform-neutral and should fit the sponsor’s validated environment, contracts, policies and regulatory obligations.
Clinical platforms
Specialist data sources
Data and analytics
Reference points
Applicability of standards, validation requirements, privacy obligations and regulatory interpretations must be confirmed by authorised quality, legal and regulatory specialists for the relevant study and jurisdiction.
Connect quality controls across the trial ecosystem
Map systems, vendors, transfers, responsibilities and evidence into one operating view.
Commercial models
Engagement Models
| Model | Best suited to | Commercial basis | Important consideration |
|---|---|---|---|
| Focused assessment | A defined quality concern or study checkpoint | Fixed scope or time used | Depends on timely evidence and stakeholder access |
| Implementation project | Control redesign, remediation or portfolio standardisation | Milestone or project fee | Scope changes and vendor dependencies require governance |
| Dedicated specialist or team | Embedded programme capacity across studies | Monthly resource or team fee | Client retains management and sponsor accountability |
| Managed quality support | Recurring monitoring, reporting and issue coordination | Monthly service fee linked to scope | Service levels, operating hours and escalation must be defined |
Illustrative situations
Practical Engagement Examples
The following examples are illustrative and do not represent named clients or guaranteed outcomes.
Late-phase lock readiness
Situation: Multiple external feeds and ageing discrepancies create uncertainty before database lock.
Scope: Critical-item review, reconciliation status, ownership, escalation and closure evidence.
Measurement: Open critical items, ageing, reconciliation completion and decision readiness.
Decentralised trial quality controls
Situation: eCOA, wearable and home-health data create new transfer and traceability risks.
Scope: Data-flow mapping, acceptance checks, exception handling and vendor oversight.
Measurement: Transfer acceptance, exception recurrence and unresolved material issues.
Portfolio rule optimisation
Situation: Studies inherit large edit-check libraries that generate inconsistent workload.
Scope: Rule rationalisation, criticality, false-positive review and governance standards.
Measurement: Rule usefulness, manual review burden and recurring issue detection.
Outcomes and measurement
Expected Outcomes and Relevant KPIs
Operational
Clearer workflows, faster triage, reduced ambiguity and more consistent cross-team coordination.
Data quality
Better visibility of missing, inconsistent, late or unreconciled critical data.
Governance
Documented ownership, escalation, decisions, vendor obligations and acceptance evidence.
Study readiness
More dependable information for analysis, database lock and oversight discussions.
| KPI | What it indicates | Baseline needed | Limitation |
|---|---|---|---|
| Critical query ageing | Speed of resolution for material data issues | Query priority and age distribution | Depends on site and vendor response |
| Reconciliation completion | Status of cross-source matching and discrepancy closure | Expected transfers and open-item inventory | Completion does not prove scientific validity |
| Recurring issue rate | Whether root causes are being controlled | Consistent issue taxonomy | Classification quality affects interpretation |
| Critical missing-data trend | Availability of data needed for safety or endpoints | Defined critical elements and expected timing | Protocol and visit context must be considered |
| Database lock readiness | Progress against agreed closure criteria | Approved readiness checklist | Requires accountable study-team judgement |
Cost planning
Pricing and Cost Factors
A written estimate should follow discovery because trial scope and operating conditions materially affect effort.
Study scope
Number of studies, phases, sites, participants, countries and protocol complexity.
Data landscape
Number of systems, external providers, transfer patterns and reconciliation requirements.
Control depth
Assessment, design, implementation, recurring review, reporting and documentation expectations.
Delivery model
Specialist roles, operating hours, onsite needs, service levels, governance and duration.
Request a scoped commercial estimate
Share the study stage, systems, vendors, primary quality concerns and expected delivery model.
Provider considerations
Why Consider DataConsultant
Evidence-led assessment
Recommendations are tied to protocols, data flows, issue records, control evidence and stakeholder decisions rather than generic maturity language.
Business and technology alignment
Clinical, statistical, quality, vendor and platform considerations are assessed together so controls are practical to operate.
Transparent delivery
Assumptions, dependencies, limitations, responsibilities and acceptance criteria are documented throughout the engagement.
Responsible delivery
Security, Quality, Privacy and Compliance Considerations
Information handling
Use confidentiality agreements, data minimisation, secure transfer, controlled credentials, encryption where appropriate, access logs, retention rules and documented access removal.
Quality controls
Apply version control, peer review, change control, traceability, approval records, segregation of duties where needed and documented validation evidence.
Privacy and residency
Confirm lawful handling, role responsibilities, residency restrictions, cross-border transfers, pseudonymisation expectations and third-party processing terms with authorised specialists.
Compliance boundaries
DataConsultant may support compliance enablement and control evidence but does not guarantee compliance, certification, security, regulatory approval, inspection outcome or legal interpretation.
Operational resilience
Define incident escalation, business continuity, backup staffing, vendor dependencies, recovery expectations and handover procedures appropriate to the service.
Delivery environment
Technology Ecosystems and Working Arrangements
The service can operate within sponsor-controlled environments, approved collaboration platforms or agreed secure workspaces, subject to access, validation and contractual requirements.
Sponsor and CRO systems
Work alongside internal teams and providers using established EDC, CTMS, eTMF, safety, analytics and quality platforms.
Controlled data exchange
Use approved channels, least-privilege access, named custodians and documented transfer or deletion procedures.
Integrated governance
Connect study-team meetings, vendor reviews, quality forums, escalation routes and programme reporting without creating unnecessary parallel governance.
Client feedback
What Clients Value in Clinical Trial Data Quality Engagements
Representative feedback is presented below to illustrate the delivery qualities organisations value in a Clinical Trial Data Quality Service engagement.
CD★★★★★
“The assessment helped us separate critical data risks from routine operational noise. Workshops connected protocol objectives, endpoint data, vendor transfers and existing controls, giving the study leadership team a clearer basis for prioritising remediation before the next major review point.”
DM★★★★★
“Stakeholder sessions were well facilitated across data management, clinical operations, safety and statistics. The decision log captured unresolved points and owners clearly, which reduced repeated discussion and helped us agree a workable reconciliation approach with the CRO and laboratory provider.”
QA★★★★★
“The governance model was practical rather than overly complex. It defined issue categories, escalation thresholds, evidence requirements and approval responsibilities while preserving sponsor oversight. Our quality and operational teams could see how the controls would work in normal study meetings.”
BS★★★★★
“The rule review challenged several checks that generated volume without supporting important analysis decisions. The revised criteria were linked to critical data, expected timing and clinical context, which gave programmers and reviewers a more defensible basis for maintaining the catalogue.”
CO★★★★★
“Implementation guidance covered dependencies, acceptance checks, vendor responsibilities and handover activities in enough detail for the programme team to mobilise. Knowledge-transfer sessions were structured around real study scenarios, which made the operating model easier for internal teams to adopt.”
CT★★★★★
“Communication remained clear as our scope changed and additional external data feeds were introduced. Documentation revisions were tracked carefully, assumptions were visible, and risks were escalated without unnecessary alarm. The final pack was professional and usable by both technical and study stakeholders.”
Frequently asked questions
Clinical Trial Data Quality Service FAQs
What is a clinical trial data quality service?
It is a structured service that assesses and improves the completeness, consistency, traceability, timeliness and fitness for purpose of data generated during a clinical trial. Work may cover quality planning, validation rules, central monitoring, reconciliation, issue management, governance, documentation and operational reporting.
Who typically buys clinical trial data quality support?
Sponsors commonly involve clinical data management, clinical operations, biostatistics, medical monitoring, pharmacovigilance, quality assurance, regulatory affairs, clinical technology and procurement. Accountable sponsorship depends on the trial portfolio, outsourcing model and governance structure.
When should a sponsor use this service?
Common triggers include protocol complexity, multiple data sources, decentralised trial components, recurring query backlogs, reconciliation problems, inspection readiness concerns, vendor changes, platform migration, database lock pressure or inconsistent quality oversight across studies.
What activities can be included?
Scope may include current-state assessment, critical data and process identification, data quality plans, edit-check review, risk indicators, medical and statistical review support, external data reconciliation, issue taxonomy, root-cause analysis, dashboards, governance forums, SOP support and knowledge transfer.
Does the service replace clinical data management?
No. It can strengthen, supplement or independently assure clinical data management, but it does not automatically replace sponsor accountability, investigator responsibilities, medical judgement, biostatistical review, safety surveillance, legal advice or regulatory decision-making.
Which clinical trial data sources can be reviewed?
Relevant sources may include EDC, eCOA, IRT or RTSM, central and local laboratory data, imaging, ECG, wearable and sensor data, safety databases, coding systems, site data, randomisation data and other protocol-defined external sources.
How are data quality rules prioritised?
Rules should be linked to protocol objectives, critical-to-quality factors, patient safety, primary and key secondary endpoints, eligibility, treatment exposure, important deviations, regulatory reporting and downstream analysis. Not every field requires the same control intensity.
How long does an engagement take?
There is no reliable fixed duration without scoping. Timing depends on trial phase, study count, protocol complexity, data-source volume, system access, documentation quality, vendor participation, remediation needs, review cycles and whether support continues through database lock.
How is pricing calculated?
Pricing is influenced by the number and phase of studies, subject and site volume, data-source complexity, platform landscape, rule inventory, reconciliation scope, reporting frequency, required specialist roles, operating hours, documentation needs and engagement model.
Can DataConsultant work with CROs and specialist vendors?
Yes. Delivery can be coordinated with CROs, laboratories, imaging providers, eCOA vendors, technology providers, statistical programmers and internal sponsor teams. Roles, access, escalation paths, evidence requirements and acceptance criteria should be agreed at the outset.
How are privacy and security handled?
The engagement can apply data minimisation, role-based access, secure transfer, controlled environments, audit trails, retention rules, incident escalation, credential management and documented access removal. Specific controls depend on sponsor policies, contracts, jurisdictions and platform capabilities.
Does DataConsultant guarantee regulatory compliance or inspection outcomes?
No. The service can support compliance enablement, control evidence and inspection readiness, but it does not provide legal advice, statutory audit, certification, regulatory approval or a guarantee of inspection outcome. Applicable obligations require authorised legal, quality and regulatory review.
What deliverables are normally provided?
Typical outputs include assessment findings, a data quality plan, critical data and process map, rule catalogue, reconciliation matrix, issue taxonomy, governance model, dashboards, risk register, remediation backlog, operating procedures, decision logs and knowledge-transfer materials.
How should outcomes be measured?
Measures may include overdue query ageing, critical issue closure, reconciliation status, edit-check effectiveness, protocol deviation trends, missing or inconsistent critical data, vendor response performance, review cycle time, database lock readiness and recurrence of root causes. Baselines and attribution limits should be documented.